Neuphoria Updates Phase 3 Trial for Social Anxiety Drug
Neuphoria’s Phase 3 AFFIRM-1 study of BNC210 for the acute treatment of social anxiety disorder failed to demonstrate efficacy....
Adarx Presents Kidney Disease Data at ASN Kidney Week 2025
ADARx will present interim Phase 1 data for ADX-038, an siRNA targeting complement factor B, at ASN Kidney Week...
Avance Clinical Launches Center to Accelerate Biotech Trials
Avance Clinical has launched an Early Phase Center of Excellence for Biotechs, bundling scientific and regulatory guidance with operational...
Veeva and OpenEvidence Form Strategic AI Partnership to Revolutionize Trial Access and Therapeutic Adoption
In a strategic move that signals a broader shift toward embedded AI in clinical workflows, Veeva Systems and OpenEvidence...
Promising Results for CRB-701 in HNSCC & Cervical Cancers
At the 3.6 mg/kg dose of CRB-701, objective response rates reached 47.6% in head and neck squamous cell carcinoma,...
Olema Oncology Data on Palazestrant Combo for Breast Cancer
In a Phase 1b/2 study of palazestrant plus ribociclib in ER+/HER2- advanced or metastatic breast cancer, the 120 mg...
Oncology Trial Reveals Promising Preliminary Phase 1 Results
In an ongoing Phase 1 trial of 12 patients with metastatic BRCA/PALB2-associated cancers (11 pancreatic ductal adenocarcinoma and one...
IO Biotech Unveils Phase 3 Cylembio Melanoma Trial Results
Cylembio plus pembrolizumab delivered a median progression-free survival of 19.4 months versus 11.0 months with pembrolizumab alone in previously...
RAPT to Report Topline Phase 2 Data for RPT904 in CSU
RAPT Therapeutics will release topline results on Monday from a partner-run Phase 2 trial of RPT904 in chronic spontaneous...
ESMO 2025: Promising RP1/Nivolumab Acral Melanoma Data
RP1 plus nivolumab produced a 44% objective response rate (8/18) in an ad hoc analysis of acral melanoma patients...